RBC Capital Reiterates Outperform on Bicycle Therapeutics, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an Outperform rating for Bicycle Therapeutics (NASDAQ:BCYC) and maintained a price target of $35.
November 01, 2024 | 4:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Bicycle Therapeutics, maintaining a $35 price target, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $35 price target by RBC Capital suggests positive sentiment and confidence in Bicycle Therapeutics' future performance. This could lead to a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100